We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Why Do Early Ovarian Cancer Detection Tests Fail?

By LabMedica International staff writers
Posted on 04 Aug 2009
Current diagnostic tests for ovarian cancer are ineffective for early detection of the disease.

A study has found that in order to significantly lower the mortality rate for the ovarian cancer, tests need to detect tumors about 200-times smaller in mass than those currently used to assess potential new tests. More...
However, the window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years.

However, it is also difficult to design an effective test for this disease because there is more than one type of ovarian cancer. The most deadly, known as serous ovarian cancer, accounts for about 50 % of all cases of ovarian cancer and is responsible for at least 80 % of deaths from the disease. In contrast to other types of ovarian tumors, which can grow to be quite large before spreading to other locations, serous ovarian tumors usually metastasize before they are diagnosed.

In its early stages symptoms of ovarian cancer are vague, and often do not occur until the tumor is already several centimeters in diameter. At this point, it may have already spread to surrounding organs and tissues. Several studies have indicated that the current screening tests deliver many false-positive results and do not reduce mortality from the disease.

Biochemistry professor Patrick Brown, M.D., Ph.D. at the Stanford University, school of medicine, (Stanford, CA, USA) and team, which included scientists from the nonprofit Canary Foundation (Palo Alto, CA, USA), performed the study on early detection of ovarian cancer.

The Canary foundation is dedicated to the early detection of many types of cancer. "We are miles away from detecting the most deadly ovarian tumors at this early stage," said Prof. Brown "but now we have a chance of actually designing an effective test that will allow us to treat them before they become deadly."

Prof. Brown added that if a blood test were to be effective it would probably require identifying new markers that are not produced by normal cells. Other possible strategies might rely on new molecular imaging methods, or fluid samples from the uterus or vagina--in which tumor markers are likely to be more concentrated.

The early detection of ovarian cancer study was published in the July 28, 2009 issue of the open-access journal PLoS Medicine.

Related Links:

Stanford University, School of medicine
Canary Foundation
PLoS Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.